Why Is LEGEND BIOTECH CORP ADR (LEGN) Stock Down Today?

Why LEGN stock is down today

Legend Biotech (LEGN) shares fell 4.95% to $20.75 in early trading on Friday, reversing a recent rally that had pushed the stock up more than 17% over the previous eight sessions. The decline followed a downgrade from Oppenheimer, which cited concerns over potential M&A activity and its impact on the company's strategic direction.

What Happened

Oppenheimer downgraded Legend Biotech stock on M&A concerns, lowering its rating to Perform with a price target of $40. This move came amid a broader shift in analyst sentiment, with several other firms also revising their price targets lower in recent days. TD Cowen maintained a Hold rating but cut its price target to $24, while RBC Capital kept an Outperform rating but lowered its target to $58. Barclays also maintained an Overweight rating but reduced its price target to $78. These adjustments reflect a cautious stance despite the company's recent earnings beat and a rare quarterly profit.

Earlier in the week, Legend Biotech had reported Q2 2026 results that exceeded expectations, with adjusted earnings per share of $0.16 and revenue of $387.5 million, driven by strong sales of its CARVYKTI product. The company's interim CEO highlighted the progress in transitioning from a capital-intensive biotech to a profitable cell therapy business. However, the recent analyst downgrades have cast some uncertainty over the stock's near-term trajectory.

What The Data Shows

The stock opened at $21.72, slightly below the previous close of $21.83, and quickly moved lower, hitting a session low of $20.74 before stabilizing at $20.75. The intraday volume of 0.7 million shares was above the 3-month average, indicating increased investor activity. Over the past 30 days, sentiment had improved slightly to 59 out of 100 from an average of 53, but recent insider transactions show two sales totaling $171,000 in the last 90 days, including a sale by the CEO on June 25.

What To Watch

With no upcoming earnings date provided and limited insider activity to monitor, investors will likely focus on the evolving analyst coverage and any further developments in the company's strategic direction. The stock remains within its 52-week range of $16.24 to $38.35, and its fundamentals continue to show strong revenue growth despite ongoing losses.